Objectives: The aim of this study was to develop and validate a population pharmacokinetic model in order to describe ritonavir-boosted saquinavir concentrations dosed twice and once daily in human immunodeficiency virus (HIV)-infected patients from the UK, Uganda and Thailand and to identify factors that may influence saquinavir pharmacokinetics.
Introduction
Saquinavir is a potent protease inhibitor used as part of combination antiretroviral therapy to treat human immunodeficiency virus (HIV) and has proven efficacy in treatment-naive and -experienced patients. 1 The pharmacokinetic profile of saquinavir is characterized by poor bioavailability due to extensive first pass and hepatic metabolism, which is improved by co-administration of low-dose ritonavir to inhibit CYP3A4 activity and transport proteins. Saquinavir/ritonavir is licensed at a recommended dose of 1000/100 mg twice daily in Europe and the USA. Despite this, once-daily doses are used in clinical practice, namely 1600/100 mg (or 1500/100 mg if 500 mg filmcoated Invirase w tablets are available) and 2000/100 mg. As a result of high interindividual variability, potential drug -drug interactions and use of unlicensed doses, saquinavir is a candidate for therapeutic drug monitoring (TDM). 2, 3 A minimum effective concentration (MEC) to sufficiently suppress viral replication has been defined for saquinavir as a trough concentration above 0.1 mg/L, 4 based on clinical studies in treatmentexperienced HIV patients receiving twice-daily therapy. 5 -7 Following approval of novel HIV drugs, the use of saquinavir in western countries has declined. However, due to lack of availability of recently approved medications in areas such as Thailand and Africa, saquinavir-boosted regimens remain a viable option. Saquinavir boosted with ritonavir is recommended as an alternative to lopinavir/ritonavir as a second-line therapy in resource-limited settings including Uganda. 8 Furthermore, in contrast to Europe and the USA, saquinavir is approved for once-daily dosing in Thailand (1600/100 and 1500/100 mg), in addition to the standard twice-daily dose. It has also been noted that Thai patients experience significantly higher saquinavir/ ritonavir concentrations compared with HIV patients from the UK administered 1600/100 mg once daily. 9 Potential factors that can influence the pharmacokinetics of boosted saquinavir regimens are important in the clinical management of HIV infection and may aid optimal dosage selection to ensure adequate drug concentrations for viral suppression. The aim of this analysis was to develop and validate a population pharmacokinetic model in order to characterize ritonavirboosted saquinavir concentrations in HIV-infected individuals from the UK, Uganda and Thailand.
Methods

Patients
Data obtained from HIV-infected males and non-pregnant females were pooled from 10 clinical studies evaluating saquinavir/ritonavir pharmacokinetics (saquinavir hard-gel capsules or 500 mg filmcoated tablets). 10 -19 Boosted saquinavir was investigated either as a sole protease inhibitor or in combination with other antiretrovirals, namely a second protease inhibitor, or under various dietary conditions and at doses of 1000/100 mg twice daily, 1600/100 mg once daily or 2000/100 mg once daily. Patients were recruited and assessed at three different sites: the UK (PK Research Ltd, St Stephen's Centre, Chelsea and Westminster Foundation Trust, London, UK), Uganda (CARE study cohort, Joint Clinical Research Centre, Kampala, Uganda) and Thailand [Thai Red Cross AIDS Research Centre and HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)]. Detailed accounts of study design, inclusion/exclusion criteria and pharmacokinetic findings of each study have been reported previously. 10 -19 Patients with active clinically significant diseases other than HIV, such as hepatitis infections or tuberculosis, were not allowed to participate. The intake of medications known to induce or inhibit protease inhibitor metabolism (such as non-nucleoside reverse transcriptase inhibitors or traditional medications) was not permitted, with the exception of drugs under investigation. Studies were approved by local Research Ethics Committees, and all individuals provided written informed consent.
Blood sampling and drug analysis
All patients were stable on a saquinavir/ritonavir-containing regimen at least 2 weeks prior to the start of each study and were administered saquinavir/ritonavir as part of combination antiretroviral therapy containing two nucleoside reverse transcriptase inhibitors or one nucleoside reverse transcriptase inhibitor plus one nucleotide reverse transcriptase inhibitor. In brief, on the day of pharmacokinetic sampling, drug intake was directly observed and timed and administered under fed conditions with a standard 40, 20 or 66 g fat-containing meal or under fasted conditions (UK), with a fatty African breakfast (Uganda) or a 10 -15 g fat-containing meal (Thailand). Venous blood samples (7 mL) were drawn and collected into heparinized tubes at the following time points:
1. UK: pre-dose (0 h) and 0. Saquinavir and ritonavir pharmacokinetics were assessed at steady state and plasma isolated (1000 g; 10 min; 48C) within 2 h of collection and stored (2708C) until analysed.
Quantification of saquinavir and ritonavir in plasma was performed by fully validated HPLC-tandem mass spectrometry (HPLC-MS/MS) methods or HPLC with ultraviolet detection (HPLC-UV), as illustrated previously. 20 -22 The majority of the plasma samples were analysed at the same laboratory in the UK with the exception of one study originating from the UK 14 and those from Thailand. 10, 18 However, all laboratories participate in the same external quality assurance programme (International Interlaboratory Quality Control Program for Therapeutic Drug Monitoring in HIV Infection, Nijmegen, The Netherlands) with acceptable performances. Details of each assay's performance have been described previously.
-22
Data analysis
Non-linear mixed effects modelling was applied using NONMEM w software (version V, level 1.1, double precision; ICON Development Solutions, Ellicott City, MD, USA) 23 by means of first-order (FO) estimation. Model fit was assessed by statistical and graphical methods. The minimal objective function value (OFV; equal to 22 log likelihood) determined by NONMEM was used as a goodness-of-fit diagnostic with a decrease in OFV of 3.84 points corresponding to a statistically significant difference between hierarchical models (P ¼ 0.05, x 2 distribution with one degree of freedom 
Pharmacokinetic model building
Initially, several structural and error models were explored using a small set of data (i.e. data obtained from one study). Once an adequately fitting structural and error model was found, each study was added consecutively in order to determine whether there were any systematic differences in patients' apparent oral clearance (CL/F) or apparent volume of distribution (V/F) between studies.
Covariate model building
The following covariates on CL/F and V/F were explored: ritonavir area under the curve over the dosing interval (AUCt: 12 or 24 h), ritonavir clearance (dose/AUCt), sex, body weight, study site (UK, Uganda and Thailand), concomitant protease inhibitor (fosamprenavir, 700 mg twice daily; atazanavir; 300, 200, 150 mg once daily) and concomitant tenofovir DF 300 mg once daily. Covariates were introduced separately and included in the model if they were statistically significant, i.e. associated with a decrease in OFV of 3.84 (P 0.05) and clinically relevant, which here we define as a change in the typical value of the pharmacokinetic parameter (i.e. CL/F) of 10% following the addition of a covariate. Once all significant and relevant covariates were incorporated, a backwards elimination step was then performed, removing covariates from the model one at a time. Covariates were only retained if removal from the model produced a significant increase in OFV of 6.63 (P 0.01) and were clinically relevant. The inclusion of covariates should also produce a reduction in variability. n, number of patients; M, male; F, female; SQV, saquinavir; RTV, ritonavir; FPV, fosamprenavir; TDF, tenofovir; ATV, atazanavir; bid, twice daily; qd, once daily; AUCt, area under the curve over the dosing interval (0-12 or 0-24 h). a n ¼ 21 evening profiles. b n ¼ 30 UK patients. c Saquinavir 500 mg film-coated tablets.
Model validation
Using parameters defined by the model, 1000 datasets were simulated at doses of 1000/100 mg twice daily, 1600/100 mg once daily and 2000/100 mg once daily (UK study site only). From the simulated data, 95% prediction intervals (P2.5 -P97.5) for each regimen were constructed. Observed data from the original dataset at the assessed doses were superimposed. At least 95% of the data points within the prediction interval, and 2.5% above and below, was indicative of an adequate model. As an additional validation process, the predictive performance of the final model was evaluated using a set of concentration-time data from the control arm of another clinical study not included in the model-building process. 24 Final model parameters were used to predict individual saquinavir concentrations of the dataset and compared with the measured concentrations. Predictive performance was assessed by calculating the mean relative prediction error (%MPE) as a measure of bias and root mean-squared relative prediction error (%RMSE) as a measure of precision. 25 
Results
Patients
Ninety-seven HIV-infected individuals (42 females) from study sites in the UK (n ¼ 52, of which 5 were Black-African), Uganda (n ¼ 18) and Thailand (n ¼ 27) receiving orally administered saquinavir/ritonavir were included in the model-building process. Patient demographics and baseline characteristics are summarized in Table 1 . Thai patients were lighter than UK and Ugandan patients, and patients from Uganda weighed less than UK patients (P 0.0012 for all comparisons; ANOVA with Bonferroni correction). Moreover, ritonavir AUCt was significantly higher in Thai patients compared with those from the UK and Uganda (P , 0.0001 and P ¼ 0.00217, respectively; ANOVA with Bonferroni correction). A median (range) of 2 (1-14) full pharmacokinetic profiles per patient were available equating to 347 profiles and 3482 concentrations in total ( Figure 1 ).
Pharmacokinetic model (FO estimation)
A one-compartment model with zero-order absorption best described the data. A one-compartment model with first-order absorption was found to be unsatisfactory (based on modelbuilding criteria), and a two-compartment model would not run. Allowing a different CL/F value for saquinavir/ritonavir 1600/ 100 and 2000/100 mg once daily improved model fit (DOFV 252.505), as did assigning a different CL/F and V/F value, respectively, to Ugandan and Thai study sites (DOFV 294.131 and 227.599, respectively) and a different V/F following a morning and evening dose of saquinavir/ritonavir 1000/100 mg twice daily (DOFV 2109.721). The addition of an absorption lag-time further improved the fit (DOFV 2398.662). Interindividual variability (IIV) and interoccasion variability (IOV) were included on CL/F and V/F (DOFV 2148.964, 21141.354 and 2121.471 with the addition of IIV V/F, IOV CL/F and IOV V/F, respectively, compared with IIV CL/F only). IIV on duration (D1) and absorption lag further improved model fit (DOFV 2120.362 and 222.040, respectively). IIV and IOV were described by an exponential model and residual error by a combined additive-proportional model. A bioavailability factor (F1) was introduced to explore the effect of a high-fat meal and fasted state on saquinavir pharmacokinetics. Compared with a standardized meal (F1 ¼ 1; 10 -40 g fat and an African breakfast), F was decreased by $40% (F1 ¼ 0.60) in the fasted state and increased by $80% (F1 ¼ 1.82) for a high-fat meal (66 g fat).
Parameter estimates for the final model are summarized in Table 2 , and the diagnostic plots are shown in Figure 2 .
Covariate model
In the univariate analysis, ritonavir AUCt on saquinavir CL/F and V/F gave the largest decrease in OFV (2155.509 and 250.632, respectively). A statistically significant, clinically relevant relationship was also found between body weight and saquinavir V/F. Sex, concomitant atazanavir (300 and 200 mg once daily) and tenofovir on saquinavir CL/F were also significant. The addition of covariates was described by linear models with the exception of ritonavir AUCt, which showed a power relationship. Following multivariate analysis and backwards elimination, only ritonavir AUCt on saquinavir CL/F and V/F remained ( Table 2 ). An example of the equation used to describe saquinavir CL/F is shown below (similarly for saquinavir V/F), along with the equation for residual variability.
where CL/F ij illustrates the saquinavir CL/F of the ith individual on the jth occasion, u 1 the initial parameter estimate, u 2 the factor associated with ritonavir AUCt on saquinavir CL/F, RTV ij the AUCt of ritonavir for the ith individual on the jth occasion, 8.25 the median ritonavir (RTV) AUCt value in mg . h/L, h i the IIV with a mean of zero and variance v 2 and k ij the IOV with a mean of zero and variance p 2 .
where Y is the final prediction, F the individual prediction and e 1 and e 2 the proportional and additive model components, respectively, with a mean of zero and variance s 
Comparison of study site
A saquinavir/ritonavir dose of 1600/100 mg once daily was common to the three evaluated study sites: UK, Uganda, Thailand. To assess the potential differences in pharmacokinetic parameters between study sites, the model was used to determine saquinavir CL/F and V/F for a typical 70 kg adult male, administered saquinavir/ritonavir 1600/100 mg once daily, without any interacting medications with a ritonavir AUC 0 -24 of 8.92 mg . h/L (mean ritonavir AUCt) and compared with the values obtained for UK patients (i.e. UK versus Uganda and UK versus Thailand; Table 3 ). Ratios associated with comparisons between study sites should be similar for population and individual predictions; however, based on the final model, discrepancies were observed. For example, the ratio of UK versus Thai patients for the population predictions of V/F was 0.9 in comparison with 1.4 for the individual predictions ( Table 3) .
The agreement between population and individual predictions was improved by splitting the patients according to the study site and by obtaining parameter estimates separately for UK, Ugandan and Thai patients, in other words, using one model but with different parameter estimates for each study site (Table 3) . Based on these estimates, an HIV patient from Thailand had an $3 times lower CL/F than an individual from the UK, whereas a UK patient had $1.5 -2-fold higher saquinavir CL/F than a Ugandan (Table 3) . Model parameters for each study site obtained separately are shown (Table 4) .
Model validation
A 95% prediction interval for each saquinavir/ritonavir regimen (1000/100 mg twice daily, 1600/100 and 2000/100 mg once daily) is shown in Figure 3 . They were generated from 1000 simulations of each regimen, one profile per patient with covariate values similar to individuals used in the model-building process (1000/100 mg twice daily, n ¼ 49; 1600/100 mg once daily, n ¼ 30; 2000/100 mg once daily, n ¼ 21). Observed data from patients used in the model-building process were superimposed onto the prediction interval. Of 1338 concentrations for 1000/100 mg twice daily, 1.05% were above P97.5 and 1.27% were below P2.5. For 1600/100 mg once daily, 2.15% of the 418 concentrations were below P2.5, whereas no concentrations were above P97.5. In contrast, 10/230 (4.35%) were below P2.5 and 4/230 (1.74%) above P97.5 for saquinavir/ritonavir 2000/100 mg once daily. This analysis suggests that the final model provided an adequate fit to the data, with 93% to 97% of the concentration data falling within the prediction intervals for all three regimens.
Furthermore, prediction intervals were also generated from 1000 simulations for Ugandan (n ¼ 18) and Thai patients (n ¼ 27) at a dose of 1600/100 mg once daily, one profile per patient. Approximately 98% of the observed saquinavir concentrations from Thai patients were within the prediction interval, whereas 92% of the concentrations from the Ugandan patients were within the 95% prediction interval (4% below P2.5 and above P97.5).
A comparison of saquinavir trough concentrations (12 or 24 h post-dose; administered twice daily or once daily, respectively) with the recommended MEC of 0.1 mg/L was also performed. Of the 347 concentration-time profiles, 65 trough concentrations were below target; 86% of which were correctly identified by the model and 14% predicted within the therapeutic range when they were, in fact, suboptimal. Of the remaining 282 trough concentrations above the MEC, the model incorrectly predicted 5% of the individual trough concentrations to be below 0.1 mg/L. The evaluation of twice-and once-daily simulated data revealed 12%, 23% and 20% of trough concentrations below the recommended MEC at a dose of 1000/100 mg twice daily, 1600/100 mg once daily and 2000/100 mg once daily, respectively, for patients from the UK. At a dose of 1600/100 mg once daily, 14% and 16% of the simulated saquinavir trough concentration data were below target for Ugandan and Thai patients, respectively.
Data from 12 additional HIV-infected individuals (1 female) receiving saquinavir/ritonavir 1000/100 mg twice daily (500 mg film-coated Invirase w tablets; 1 profile per patient, 120 concentrations) were used to further validate the model. 24 Median (range) age, weight, body mass index (BMI) and ritonavir AUC 0 -12 were 41 years (27 -61), 70 kg (64 -104), 24 kg/m 2 (21 -34) and 7.5 mg . h/L (2.0 -14.7), respectively. Baseline CD4 cell count ranged between 338 and 779 cells/mm 3 , and 9 of the 12 patients had undetectable viraemia (,50 copies/mL); three patients had detectable HIV-RNA values of 88, 662 and 878 copies/mL. The study set out to investigate the effect of omeprazole on saquinavir/ritonavir pharmacokinetics; therefore, only data from the control phase of the study were used for validation (i.e. saquinavir/ritonavir alone). A plot of individual saquinavir predictions versus measured saquinavir concentrations is shown (Figure 4) . The predictive performance of the model was acceptable, providing precise (%RMSE: 15.9%) and unbiased (%MPE, 95% CI: 1.1%, 21.8 to 4.0) predictions. Individual concentrations for one patient were poorly predicted by the model compared with other patients, removal of this individual resulted in improved predictive performance (%RMSE: 11.4%; %MPE, 95% CI: 1.4%, 20.7 to 3.6). Compared with the 11 patient profiles adequately predicted by the model, this patient had considerably lower saquinavir concentrations attributable to a higher CL/F (36-85 versus 240 L/h).
Discussion
A model to describe the pharmacokinetics of ritonavir-boosted saquinavir regimens has been developed and validated in HIV-infected patients from the UK, Uganda and Thailand. Ritonavir AUC over the dosing interval was significantly associated with saquinavir pharmacokinetics and described some of the variability in concentrations, decreasing saquinavir IIV on CL/F by 23% and IOV on CL/F and V/F by 11% and 8%, respectively.
Few publications are available evaluating the population pharmacokinetics of saquinavir, and none to date has investigated boosted regimens at the currently licensed dose (1000/100 mg twice daily) or following once-daily treatment. Furthermore, this analysis has the added advantage of determining saquinavir population pharmacokinetics in patients from three different continents, allowing exploration of ethnic differences. As a result of different doses and dosing schedules, it is difficult to compare model parameters with those outlined in the literature. Vanhove et al. 26 determined a CL/F of 989 L/h in HIV patients following steady-state dosing of hard gel saquinavir capsules 600 mg (unboosted) three times a day, and an analysis using MONOLIX software estimated saquinavir CL/F to be 1.26 L/h in 100 HIV patients administered a single dose of saquinavir (600 mg) and 200 mL of grapefruit juice. 27 However, similar to the present analysis, IIV in pharmacokinetic parameters was high ($52% to 120%). 26, 27 An analysis using the Markov chain Monte Carlo approach assessed saquinavir pharmacokinetics from Phase I studies in healthy volunteers receiving saquinavir 600 mg single dose, multiple dose or 12 mg intravenously. The authors concluded that saquinavir exhibits complex and highly variable behaviour and used a twocompartment biphasic or monophasic zero-order absorption model to describe the data. 28 The study also estimated saquinavir clearance and volume of distribution using the bioavailability of 4% (F ¼ 0.039). 28 For the present analysis, a two-compartment model was not possible, and the presence of ritonavir alters the clearance and bioavailability of saquinavir. The bioavailability of saquinavir coadministered with low-dose ritonavir is not known.
Body weight 26 and BMI, 27 respectively, were associated with saquinavir pharmacokinetics in two population pharmacokinetic studies; however, our analysis identified ritonavir AUCt as the most important covariate. Body weight on saquinavir V/F was significant and clinically relevant in the univariate analysis; however, in the presence of ritonavir AUCt, the addition of body weight, although significant (i.e. decreased OFV), did not really influence the predictions or improve model fit, and therefore it was not included. It is possible that in the absence of ritonavir, the effect of body weight is more important; furthermore, the analysis by Lavielle et al. 27 included data from a study investigating saquinavir pharmacokinetics in patients with diarrhoea and/or wasting, 29 so it is probably not surprising that CL/F was associated with BMI.
Some underestimation of predicted concentrations was evident at the higher concentration range. Potentially, this could be a result of the estimation method used. The model-building process was implemented with FO estimation and not first-order conditional estimation (FOCE) with interaction. The FO method can be prone to underestimation; however, we did attempt the analysis using FOCE with interaction. NONMEM struggled to converge with increasing model complexity, particularly following the addition of IIV to D1, absorption lag or both and, as a result, model fit was better using FO estimation compared with FOCE. Furthermore, saquinavir pharmacokinetics may be influenced by other covariates that were not collected or are yet to be identified. Ritonavir AUCt was the most significant covariate; however, it was unlikely that it would describe all of the variability, particularly when dealing with a drug such as saquinavir, which is inherently poorly bioavailable and is characterized by an erratic pharmacokinetic profile. Ritonavir acts to improve saquinavir pharmacokinetics and to increase bioavailability; however, it must be noted that through this mechanism, there will be differential inhibition of saquinavir metabolism and transport, potentially complicating the system. This by no means undermines the clinical application of the model as validation was successful, and good agreement was observed between measured and individual predicted saquinavir concentrations.
The 2NN study reported $11% and 28% higher clearance of the non-nucleoside reverse transcriptase inhibitor, nevirapine, in South American and Western HIV patients, respectively, compared with Thai and South African individuals. 30 A study evaluating indinavir alone and boosted with ritonavir in HIV-infected patients from Thailand observed a 20% higher indinavir maximum concentration when compared with the historical data from Caucasian patients. 31 Furthermore, boosted saquinavir AUC 0 -24 and minimum concentration (1600/100 mg once daily) were $3-fold higher in Thai patients compared with those from the UK in an analysis performed by Autar et al. 9 Some of the data were also included in the present population pharmacokinetic model and support the finding that saquinavir CL/F in Thai patients was three times lower than that in the UK patients. UK patients also had a higher saquinavir CL/F compared with Ugandan patients; however, this was not as pronounced as the differences observed with individuals from Thailand. Furthermore, saquinavir V/F was slightly lower in Thai patients compared with those from the UK, but the difference was not as large as that noted for saquinavir CL/F. It is well established that saquinavir absorption is improved with food, 32 particularly high fat; 17 however, it is highly unlikely that this contributes to higher concentrations seen in Thai patients as the fat content was lower (10 -15 g) compared with the standardized meal UK patients received (20-40 g ). The fat content of an African fatty breakfast is not known. As also suggested by Autar et al., the underlying mechanisms resulting in pharmacokinetic disparities between study sites are probably a combination of pharmacogenomic and environmental/lifestyle factors associated with ethnicity. Discrepancies were noted between population and individual prediction ratios when comparing CL/F and V/F between study sites. This was somewhat amended by splitting the data by study site and fitting the model to each site separately, i.e. one model but using different parameter estimates for each study site. The model still produced an adequate fit to the data as confirmed by the validation steps. IIV CL/F and V/F were highest for Thai patients and lowest for Ugandan patients. However, the duration of zero-order infusion was highly variable for Ugandans, and IIV on absorption lag was negligible and therefore removed. For all patients, few samples were taken during the absorption phase, potentially making it more difficult to fully characterize and resulting in over-prediction at earlier time points, particularly for 1600/100 and 2000/100 mg once daily. If resources permit, it may be prudent to sample more frequently during the absorption phase for drugs such as saquinavir, to allow for better characterization of earlier concentrations. The reason for the initial miss-fit of the data is not known, but could potentially be attributed to an unknown covariate skewing the population predictions. The antiretrovirals used, particularly ritonavir, require refrigerated storage, but those administered to Ugandan patients will have been subjected to erratic electricity supply or disruptions in the cold chain, potentially influencing the model predictions.
The potential for once-daily treatment still remains an important issue for antiretroviral therapy. With the exception of atazanavir, concern surrounds the lower trough concentrations obtained when moving from twice-daily to once-daily dosing of boosted protease inhibitors. A recent article assessed the pharmacokinetic forgiveness or robustness of boosted saquinavir/ ritonavir regimens and showed that 1600/100 and 2000/100 mg once daily remained below the recommended saquinavir MEC (0.1 mg/L) for a longer length of time compared with 1000/100 mg twice daily. 33 The length of time below target was longest for 1600/100 mg once daily. 33 This reflects the potential window of opportunity for viral escape and resistance to develop. From the simulated data, a higher percentage of patients were below target for 1600/100 mg once daily compared with the standard twice-daily dose and 2000/100 mg once daily. It has been suggested that for some patients, once-daily dosing may not be optimal and that Thai patients may be better suited to the once-daily regimen as a result of higher concentrations. However, it should also be noted (but recognizing the high additive residual error) that $16% of the simulated troughs from Thai patients and 14% from Ugandans were below the recommended MEC and so once-daily dosing may only be appropriate for specific individuals or where TDM services are available. Routine TDM is not currently considered a viable option in resourcelimited settings; however, the development of filter paper methodologies for the collection of pharmacokinetic samples coupled with population modelling may improve the feasibility of routine TDM for some patients in developing countries. Patient adherence or non-adherence to therapy can also influence model predictions. Adherence data were not available for the current dataset, but all clinical studies were carefully controlled, and when patients were not present at the study centre, adherence was monitored by means of pill counts and diaries. It has been shown that model estimation can be improved by incorporation of actual patient dosing history using electronic monitoring reported times. 34 In conclusion, a population pharmacokinetic model to predict the pharmacokinetics of ritonavir-boosted saquinavir dosed twice and once daily has been developed and validated in HIV-infected adults. Ritonavir AUCt was significantly associated with saquinavir pharmacokinetics. Due to availability of newer agents, saquinavir is not as commonly used in clinical practice in western countries. However, use in many developing countries will continue and so the model is applicable globally. The model could be used for dosage adaptation following TDM and to assess patients' suitability for once-daily boosted saquinavir therapy. The analysis also underscores the importance of pharmacokinetic studies in diverse patient populations.
